Intensification of polypharmacy glucose-lowering treatment in type-2 diabetes: When to be cautious?

摘要

Type 2 diabetes is a condition in which morbidity-mortality remains high, despite a trend to improvement in the last 10 years. The hazard ratios for cause-specific death, according to baseline diabetes status, among 820,900 people in 97 prospective studies, recently published by the Emerging Risk Factors Collaboration group [1], have confirmed the well known excess risk for vascular disease but have also shown that diabetes is associated with substantial premature death from non-vascular cause such as cancers, infectious diseases, and degenerative disorders.